Infographic | June 15, 2020

The Importance Of Final Dosage Form For Clinical Trial Material

Source: ISR Reports

In Q4, 2019 ISR asked 100 outsourcers of clinical manufacturing how important it is for the clinical trial material, or IMP, to be in its final dosage form. 44% of respondents said it is very-extremely important for the IMP to be in the final dosage form. Another 47% said it is important. To learn how dosage form influences service provider selection and much more, follow the link to the Clinical Manufacturing Market Dynamics and Service Provider Benchmarking  report preview.

access the Infographic!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Pharmaceutical Online? Subscribe today.

Subscribe to Pharmaceutical Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Pharmaceutical Online